Beeline Medicines secured an additional $126.3 million in a Series A extension, bringing total funding to $426.3 million as the company advances autoimmune programs. The financing supports ongoing and planned clinical development, including additional trials timed around upcoming data readouts. Beeline is a Bristol Myers Squibb–linked spinout that began with licensed autoimmune assets and has continued to expand its internal strategy around multiple human-tested candidates. The company’s updated portfolio includes afimetoran for lupus and additional programs in human testing and preclinical development. The round adds to a broader pattern of late-Stage Series A tailwinds for platform-light biotechs with clear clinical catalysts, supported by recurring interest from large institutional backers.